Positron emission tomography in premotor Parkinson's disease

https://doi.org/10.1016/S1353-8020(08)70041-5Get rights and content

Abstract

Functional imaging can be used to detect preclinical evidence of dopamine deficiency in people deemed to be at increased risk of Parkinson's disease (PD) based on genetic or environmental risk, or because they have clinical features such as REM sleep behaviour disorder that may be a harbinger of PD. Positron emission tomography (PET) using [11C]dihydrotetrabenazine to label the vesicular monoamine transporter type 2 (VMAT2), a variety of 11C- or 18 F-labeled ligands for the membrane dopamine transporter (DAT), or 6-[18F]fluoro-L-dopa (FD), which assesses uptake and decarboxylation of levodopa as well as vesicular storage of radiolabeled dopamine, can all be used, and all provide comparable, but somewhat different information. DAT binding using either PET or SPECT appears to be the most sensitive marker of dopamine denervation, while FD uptake is subject to compensatory upregulation and its reduction may more closely herald the onset of clinical disease. Alterations in glucose metabolism and in dopamine release also occur in the asymptomatic hemisphere of subjects with unilateral PD. An interesting potential application of PET is the determination of non-dopaminergic abnormalities that correlate with the presence of clinically apparent pre-motor symptoms of PD.

References (26)

  • H Braak et al.

    Staging of brain pathology related to sporadic Parkinson' disease

    Neurobiol Aging

    (2003)
  • R Hilker et al.

    [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson' disease

    Clin Neurol Neurosurg

    (2003)
  • VL Marshall et al.

    Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging

    Nucl Med Commun

    (2006)
  • CS Lee et al.

    In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson' disease

    Ann Neurol

    (2000)
  • P Piccini et al.

    The role of inheritance in sporadic Parkinson' disease: evidence from a longitudinal study of dopaminergic function in twins

    Ann Neurol

    (1999)
  • A Laihinen et al.

    Risk for Parkinson' disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET

    J Neurol

    (2000)
  • DB Calne et al.

    Positron emission tomography after MPTP: observations relating to the cause of Parkinson' disease

    Nature

    (1985)
  • DJ Doudet et al.

    Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride

    Synapse

    (2002)
  • AP Strafella et al.

    Corticostriatal functional interactions in Parkinson' disease: a rTMS/[11C]raclopride PET study

    Eur J Neurosci

    (2005)
  • JR Moeller et al.

    Divergent expression of regional metabolic topographies in Parkinson' disease and normal ageing

    Brain

    (1997)
  • C Tang et al.

    Hemiparkinsonism: Parallel longitudinal changes in hemispheric striatal DAT binding and glucose metabolism

    Neurology

    (2006)
  • FJ Vingerhoets et al.

    Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

    Ann Neurol

    (1994)
  • JR Adams et al.

    PET in LRRK2 mutations: comparison to sporadic Parkinson' disease and evidence for presymptomatic compensation

    Brain

    (2005)
  • Cited by (0)

    View full text